siRNA-mediated silencing of Wnt5a regulates inflammatory responses in atherosclerosis through the MAPK/NF-κB pathways

International Journal of Molecular Medicine

Volumn 34, Issue 4, 2014, Pages 1147-1152

  Yang, Lei ^a   Chu, Yingjie ^a   Wang, Yuhang ^a   Zhao, Xiangmei ^a   Xu, Wenke ^a   Zhang, Peirong ^a   Liu, Xiaoyu ^a   Dong, Shujuan ^a   He, Wenqi ^a   Gao, Chuanyu ^a  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Atherosclerosis; Inflammation; Small interfering RNA; Wnt5a

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CYCLOOXYGENASE 2; EOSIN; GELATINASE A; GELATINASE B; HEMATOXYLIN; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATE BUFFERED SALINE; SMALL INTERFERING RNA; TRIACYLGLYCEROL; VIRUS VECTOR; WNT5A PROTEIN; AUTACOID; LIPID; WNT PROTEIN; WNT5A PROTEIN, MOUSE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; GENETIC TRANSFECTION; INFLAMMATION; LIPID BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAINING; VIRAL GENE DELIVERY SYSTEM; ADENOVIRIDAE; ANIMAL; ATHEROSCLEROSIS; BLOOD; C57BL MOUSE; DEFICIENCY; ENZYMOLOGY; METABOLISM; PATHOLOGY;

ADENOVIRIDAE; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; INFLAMMATION; INFLAMMATION MEDIATORS; LIPIDS; MALE; MAP KINASE SIGNALING SYSTEM; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PLAQUE, ATHEROSCLEROTIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84907472612     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1860     Document Type: Article

References (28)

1. Glass CK and Witztum JL: Atherosclerosis. the road ahead. Cell 104: 503-516, 2001.
2. Li AC and Glass CK: The macrophage foam cell as a target for therapeutic intervention. Nat Med 8: 1235-1242, 2002. (Pubitemid 35373554)
3. Kikuchi A, Yamamoto H, Sato A and Matsumoto S: Wnt5a: its signalling, functions and implication in diseases. Acta Physiol (Oxf) 204: 17-33, 2012.
4. Sen M, Lauterbach K, El-Gabalawy H, et al: Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci USA 97: 2791-2796, 2000. (Pubitemid 30159250)
5. Christman MA II, Goetz DJ, Dickerson E, et al: Wnt5a is expressed in murine and human atherosclerotic lesions. Am J Physiol Heart Circ Physiol 294: H2864-H2870, 2008.
6. Reischl J, Schwenke S, Beekman JM, et al: Increased expression of Wnt5a in psoriatic plaques. J Invest Dermatol 127: 163-169, 2007. (Pubitemid 46005674)
7. Pereira C, Schaer DJ, Bachli EB, Kurrer MO and Schoedon G: Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol 28: 504-510, 2008.
8. Halleskog C, Dijksterhuis JP, Kilander MB, et al: Heterotrimeric G protein-dependent WNT-5A signaling to ERK1/2 mediates distinct aspects of microglia proinflammatory transformation. J Neuroinflammation 9: 111, 2012.
9. Kim J, Kim J, Kim DW, Ha Y, et al: Wnt5a induces endothelial inflammation via beta-catenin-independent signaling. J Immunol 185: 1274-1282, 2010.
10. Jung YS, Lee HY, Kim SD, et al: Wnt5a stimulates chemotactic migration and chemokine production in human neutrophils. Exp Mol Med 45: e27, 2013.
11. Malgor R, Bhatt PM, Connolly BA, et al: Wnt5a, TLR2 and TLR4 are elevated in advanced human atherosclerotic lesions. Inflamm Res 63: 277-285, 2014.
12. Yan X, Baxter RC, Perbal B and Firth SM: The aminoterminal insulin-like growth factor (IGF) binding domain of IGF binding protein-3 cannot be functionally substituted by the structurally homologous domain of CCN3. Endocrinology 147: 5268-5274, 2006. (Pubitemid 44790582)
13. Libby P, Ridker PM and Hansson GK: Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54: 2129-2138, 2009.
14. Kutuk O and Basaga H: Inflammation meets oxidation: NF-kappaB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med 9: 549-557, 2003. (Pubitemid 38017194)
15. Chan ED and Riches DW: IFN-gamma + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. Am J Physiol Cell Physiol 280: C441-C450, 2001.
16. Schönbeck U, Sukhova GK, Graber P, Coulter S and Libby P: Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155: 1281-1291, 1999. (Pubitemid 29488935)
17. Burleigh ME, Babaev VR, Oates JA, et al: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptordeficient mice. Circulation 105: 1816-1823, 2002. (Pubitemid 34408892)
18. Burleigh ME, Babaev VR, Yancey PG, et al: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 39: 443-452, 2005. (Pubitemid 41133730)
19. Gosling J, Slaymaker S, Gu L, et al: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103: 773-778, 1999. (Pubitemid 29152622)
20. Falk E: Pathogenesis of atherosclerosis. J Am Coll Cardiol 47 (Suppl 8): C7-C12, 2006.
21. Davies MJ: The pathophysiology of acute coronary syndromes. Heart 83: 361-366, 2000.
22. Schaar JA, Muller JE, Falk E, et al: Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J 25: 1077-1082, 2004. (Pubitemid 38869428)
23. Ylä-Herttuala S, Bentzon JF, Daemen M, et al: Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. Thromb Haemost 106: 1-19, 2011.
24. Naghavi M, Libby P, Falk E, et al: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 108: 1664-1672, 2003. (Pubitemid 37243650)
25. Newby AC: Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 28: 2108-2114, 2008.
26. Bond M, Fabunmi RP, Baker AH and Newby AC: Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 435: 29-34, 1998. (Pubitemid 28432009)
27. Wang J, Zhang R, Xu Y, et al: Genistein inhibits the development of atherosclerosis via inhibiting NF-kappaB and VCAM-1 expression in LDLR knockout mice. Can J Physiol Pharmacol 86: 777-784, 2008.
28. Muslin AJ: MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond) 115: 203-218, 2008.